Predictive factors for radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs (bDMARDs): Results of 3 to 4 years of follow-up

References

• Drossaers-Bakker KW, Kroon HM, Zwinderman AH, Breedveld FC, Hazes JM. Radiographic damage of large joints in long-term rheumatoid arthritis and its relation to function. Rheumatology (Oxford). 2000;39(9):998–1003.
   PubMed Web of Science ®Google Scholar
• Kuper HH, van Leeuwen MA, van Riel PL, Prevoo ML, Houtman PM, Lolkema WF, et al. Radiographic damage in large joints in early rheumatoid arthritis: relationship with radiographic damage in hands and feet, disease activity, and physical disability. Br J Rheumatol. 1997;36(8):855–60.
   PubMedGoogle Scholar
• Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B., for the BARFOT study group. Prediction of radiographic outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004;63:1090–5.
   PubMed Web of Science ®Google Scholar
• Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):196–201.
   PubMed Web of Science ®Google Scholar
• Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiographical outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2006;65(4):453–8.
   PubMed Web of Science ®Google Scholar
• Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis. 2008;67(2):212–7.
   PubMed Web of Science ®Google Scholar
• Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;66(1):34–45.
   PubMed Web of Science ®Google Scholar
• Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford). 2006;46(2):342–9.
   PubMed Web of Science ®Google Scholar
• Courvoisier N, Dougados M, Cantagrel A, Goupille P, Meyer O, Sibilia J, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2008;10(5):R106.
   PubMed Web of Science ®Google Scholar
• Markatseli TE, Voulgari PV, Alamanos Y, Drosos AA. Prognostic factors of radiological damage in rheumatoid arthritis: a 10-year retrospective study. J Rheumatol. 2011;38(1):44–52.
   PubMed Web of Science ®Google Scholar
• de Punder YM, Jansen TL, van Ede AE, den Broeder AA, van Riel PL, Fransen J. Personalizing treatment targets in rheumatoid arthritis by using a simple prediction model. J Rheumatol. 2015;42(3):398–404.
   PubMed Web of Science ®Google Scholar
• Mottonen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis. 1988;47(8):648–53.
   PubMed Web of Science ®Google Scholar
• Scott DL, Coulton BL, Popert AJ. Long term progression of joint damage in rheumatoid arthritis. Ann Rheum Dis. 1986;45(5):373–8.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Aoki Y, Sonobe M, Takahashi H, Saito M, Terayama K, et al. Radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying anti-rheumatic drugs. Mod Rheumatol. 2016;26(4):517–21.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Aoki Y, Terayama K, Sonobe M, Takahashi H, Saito M, et al. Health assessment questionnaire-disability index (HAQ-DI) score at the start of biological disease-modifying antirheumatic drug (bDMARD) therapy is associated with radiographic progression of large joint damage in patients with rheumatoid arthritis. Mod Rheumatol. 2017;27(6):967–72.
   PubMed Web of Science ®Google Scholar
• Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659–62.
   PubMed Web of Science ®Google Scholar
• Larsen A, Edgren J, Harju E, Laasonen L, Reitamo T. Interobserver variation in the evaluation of radiologic changes of rheumatoid arthritis. Scand J Rheumatol. 1979;8(2):109–12.
   PubMed Web of Science ®Google Scholar
• Seki E, Matsushita I, Sugiyama E, Taki H, Shinoda K, Hounoki H, et al. Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol. 2009;28(4):453–60.
   PubMed Web of Science ®Google Scholar
• Dirven L, van den Broek M, Kroon HM, Grillet BA, Han KH, Kerstens PJ, et al. Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints. Rheumatology (Oxford). 2012;51(12):2262–8.
   PubMed Web of Science ®Google Scholar
• van den Broek M, Dirven L, Kroon HM, Kloppenburg M, Ronday HK, Peeters AJ, et al. Early local swelling and tenderness are associated with large-joint damage after 8 years of treatment to target in patients with recent-onset rheumatoid arthritis. J Rheumatol. 2013;40(5):624–9.
   PubMed Web of Science ®Google Scholar
• de Jong Z, Munneke M, Vilim V, Zwinderman AH, Kroon HM, Ronday HK, et al. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis–data from the RAPIT study. Rheumatology (Oxford). 2008;47(6):868–71.
   PubMed Web of Science ®Google Scholar
• Matsushita I, Motomura H, Seki E, Kimura T, Radiographic changes and factors associated with subsequent progression of damage in weight-bearing joints of patients with rheumatoid arthritis under TNF-blocking therapies-three-year observational study. Mod Rheumatol. 2016;26:1–6. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Suto T, Okamura K, Yonemoto Y, Okura C, Tsushima Y, Takagishi K. Prediction of large joint destruction in patients with rheumatoid arthritis using 18F-FDG PET/CT and disease activity score. Medicine (Baltimore). 2016;95(7):e2841.
   PubMed Web of Science ®Google Scholar
• Suto T, Yonemoto Y, Okamura K, Okura C, Kaneko T, Kobayashi T, et al. Predictive factors associated with the progression of large-joint destruction in patients with rheumatoid arthritis after biologic therapy: a post-hoc analysis using FDG-PET/CT and the ARASHI (assessment of rheumatoid arthritis by scoring of large-joint destruction and healing in radiographic imaging) scoring method. Mod Rheumatol. 2017;27(5):820–7.
   PubMed Web of Science ®Google Scholar
• Norton S, Fu B, Scott DL, Deighton C, Symmons DP, Wailoo AJ, et al. Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts. Semin Arthritis Rheum. 2014;44(2):131–44.
   PubMed Web of Science ®Google Scholar
• Kanbe K, Oh K, Chiba J, Inoue Y, Taguchi M, Yabuki A. Efficacy of golimumab for preventing large joint destruction in patients with rheumatoid arthritis as determined by the ARASHI score. Mod Rheumatol. 2017;27(6):938–45.
   PubMed Web of Science ®Google Scholar